Hepatitis: Kurai O

Ohtani H, Yamazaki O, Matsuyama M, Horii K, Shimizu S, Oka H, Nebiki H, Kioka K, Kurai O, Kawasaki Y, Manabe T, Murata K, Matsuo R, Inoue T. · Department of Surgery, Osaka City General Hospital, 2-13-22 Miyakojimahondori, Japan. · Surg Today. · Pubmed #16341493 No free full text.

Abstract: A spontaneous regression of hepatocellular carcinoma is an extremely rare phenomenon. A 69-year-old Japanese man with hepatitis C virus-related chronic hepatitis presented with a liver tumor. We diagnosed the tumor to be hepatocellular carcinoma in the course of spontaneous regression, by imaging studies and changes in the tumor markers. Because the possible presence of viable cancer cells could not be ruled out, we recommended surgery. He refused all treatments at first, but finally agreed to undergo surgery about 10 months after presentation. A hepatectomy was performed. Histologically, no viable tumor cells were found. In our case, the vascularity of the tumor according to the imaging findings was followed up during the clinical course. The patient is now doing well and without any evidence of recurrence at 37 months after surgery.

Oiya H, Kioka K, Nakai T, Aoki T, Kawasaki Y, Kurai O, Nebiki H, Okawa K, Oka H, Harihara S, Kawai S, Yamasaki O, Inoue T, Kuroki T. · Department of Gastroenterology, Osaka City General Hospital. · Nippon Shokakibyo Gakkai Zasshi. · Pubmed #10879087 No free full text.

This publication has no abstract.

Kioka K, Moriyoshi Y, Nakai T, Sano K, Aoki T, Kurai O, Nebiki H, Okawa K, Oka H, Harihara S, So K, Kuroki T. · Department of Gastroenterology, Osaka City General Hospital. · Nippon Shokakibyo Gakkai Zasshi. · Pubmed #10332200 No free full text.

Abstract: The prevalence and risk factors of hypertriglyceridemia during the administration of interferon (IFN) were examined in 78 patients with chronic hepatitis C who were treated with 6 MU of IFN-beta once or 3 MU of IFN-beta twice a day for 6 weeks. Hypertriglyceridemia (serum triglyceride (TG) above 150 mg/dl) was found before the start of IFN treatment in 9% of the patients. During the administration of IFN, elevation of serum TG above 150 mg/dl was found in 82% of patients. In addition, serum TG level exceeded 500 mg/dl at least once during the administration of IFN in 13% of patients. On stepwise multiple regression analysis, three risk factors, high serum TG value before the administration of IFN, high ALT value before the administration of IFN, and divided administration of IFN-beta twice daily were found to be associated with hypertriglyceridemia during IFN administration.